it should once covid is over. revenue is growing over 200% in the last report and automation is helping improve this. gross profit margin headed to positive with this trend. it will be profitable in FY21/FY22.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%